Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population

Hypertension Research

Volumn 34, Issue 10, 2011, Pages 1141-1146

  Nakayama, Hiroyuki ^a   Nagai, Hiromi ^a   Matsumoto, Kyotaka ^a   Oguro, Ryosuke ^a   Sugimoto, Ken ^a   Kamide, Kei ^a   Ohishi, Mitsuru ^a   Katsuya, Tomohiro ^a   Okamoto, Hiroshi ^b   Maeda, Makiko ^c   Komamura, Kazuo ^d   Azuma, Junichi ^c   Rakugi, Hiromi ^a   Fujio, Yasushi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HOKKAIDO MEDICAL CENTER   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

diabetes mellitus; diastolic function; osteopontin; polymorphism

Indexed keywords

GUANINE; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENE INSERTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART LEFT VENTRICLE FILLING; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DIASTOLE; FEMALE; GENOTYPE; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; JAPAN; MALE; MIDDLE AGED; OSTEOPONTIN; PREVALENCE; PROMOTER REGIONS, GENETIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80053468046     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.102     Document Type: Article

References (44)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
2. Lloyd-Jones DM, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D, Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-3072. (Pubitemid 35440290)
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402. (Pubitemid 35239711)
4. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-327. (Pubitemid 38167688)
5. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl JMed 2006; 355: 251-259. (Pubitemid 44079340)
6. ZileMR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
7. von Bibra H, St John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 2010; 53: 1033-1045.
8. Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000; 47: 274-283. (Pubitemid 30625290)
9. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, Maeno T, Nishida T, Kubota S, Takigawa M, Kurabayashi M. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007; 49: 1120-1127. (Pubitemid 351664300)
10. Sakata Y, Masuyama T, Yamamoto K, Nishikawa N, Yamamoto H, Kondo H, Ono K, Otsu K, Kuzuya T, Miwa T, Takeda H, Miyamoto E, Hori M. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 2000; 102: 2269-2275.
11. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-1482. (Pubitemid 24003267)
12. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 1055-1061. (Pubitemid 32422899)
13. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 624-628. (Pubitemid 30151673)
14. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001; 88: 1080-1087. (Pubitemid 34137122)
15. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 2004; 44: 826-831. (Pubitemid 39577407)
16. Renault MA, Robbesyn F, Réant P, Douin V, Daret D, Alliè res C, Belloc I, Couffinhal T, Arnal JF, Klingel K, Desgranges C, Dos Santos P, Charpentier F, Gadeau AP. Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy. Circ Heart Fail 2010; 3: 431-439.
17. Sato M, Morii E, Komori T, Kawahata H, Sugimoto M, Terai K, Shimizu H, Yasui T, Ogihara H, Yasui N, Ochi T, Kitamura Y, Ito Y, Nomura S. Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 1998; 17: 1517-1525. (Pubitemid 28472756)
18. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003; 278: 48684-48689. (Pubitemid 41079508)
19. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004; 20: 87-96.
20. Brenner D, Labreuche J, Touboul PJ, Schmidt-Petersen K, Poirier O, Perret C, Schönfelder J, Combadière C, Lathrop M, Cambien F, Brand-Herrmann SM, Amarenco P, GENIC Investigators. Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke 2006; 37: 1691-1696. (Pubitemid 44297714)
21. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S, Fujiwara K. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 381-388. (Pubitemid 40723929)
22. Hendig D, Arndt M, Szliska C, Kleesiek K, Gö tting C. SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem 2007; 53: 829-836. (Pubitemid 46744237)
23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl 1): S5-20.
24. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202. (Pubitemid 43189763)
25. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ, American Society of Echocardiography. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17: 1086-1119.
26. Cooper JW, Nanda NC, Philpot EF, Fan P. Evaluation of valvular regurgitation by color Doppler. J Am Soc Echocardiogr 1989; 2: 56-66.
27. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, Battistelli M, Bartoccini C, Porcellati C. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994; 74: 714-719. (Pubitemid 24298928)
28. Senior R, Galasko G, Hickman M, Jeetley P, Lahiri A. Community screening for left ventricular hypertrophy in patients with hypertension using hand-held echocardiography. J Am Soc Echocardiogr 2004; 17: 56-61. (Pubitemid 38064116)
29. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 1987; 9(2 Part 2): II19-II26.
30. Redfield MM. Understanding 'diastolic' heart failure. N Engl J Med 2004; 350: 1930-1931.
31. Singh M, Foster CR, Dalal S, Singh K. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol 2010; 48: 538-543.
32. Flesch M, Schiffer F, Zolk O, Pinto Y, Stasch JP, Knorr A, Ettelbrü ck S, Böhm M. Angiotensin receptor antagonismand angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 1997; 15: 1001-1009. (Pubitemid 27399815)
33. Bernal J, Pitta SR, Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs 2006; 6: 373-381. (Pubitemid 46072393)
34. Abe K, Nakashima H, Ishida M, Miho N, Sawano M, Soe NN, Kurabayashi M, Chayama K, Yoshizumi M, Ishida T. Angiotensin II-induced osteopontin expression in vascular smooth muscle cells involves Gq/11, Ras, ERK, Src and Ets-1. Hypertens Res 2008; 31: 987-998. (Pubitemid 351895043)
35. Lorenzen JM, Neunhö ffer H, David S, Kielstein JT, Haller H, Fliser D. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis 2010; 209: 184-188.
36. Shen Q, Christakos S. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem 2005; 280: 40589-40598. (Pubitemid 41780549)
37. Marciano R, D'Annunzio G, Minuto N, Pasquali L, Santamaria A, Di Duca M, Ravazzolo R, Lorini R. Association of alleles at polymorphic sites in the osteopontin encoding gene in young type 1 diabetic patients. Clin Immunol 2009; 131: 84-91.
38. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 1994; 17: 633-639. (Pubitemid 24198025)
39. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-3223.
40. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
41. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Shinozaki T, Kagaya Y, Watanabe J, Shimokawa H. Diabetes mellitus accelerates left ventricular diastolic dysfunction through activation of the renin-angiotensin system in hypertensive rats. Hypertens Res 2009; 32: 472-480.
42. Subramanian V, Krishnamurthy P, Singh K, Singh M. Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. Am J Physiol Heart Circ Physiol 2007; 292: H673-H683. (Pubitemid 46105231)
43. de las Fuentes L, Gu CC, Mathews SJ, Reagan JL, Ruthmann NP, Waggoner AD, Lai CF, Towler DA, Dávila-Román VG. Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness. J Am Soc Echocardiogr 2008; 21: 954-960.
44. Liu CC, Huang SP, Tsai LY, Wu WJ, Juo SH, Chou YH, Huang CH, Wu MT. The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis. Clin Chim Acta 2010; 411: 739-743.